Chelators Controlling Metal Metabolism and Toxicity Pathways: Applications in Cancer Prevention, Diagnosis and Treatment

REFERENCES

• Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R, Jacks T. Restoration of p53 function leads to tumour regression in vivo. Nature 2007; 445(7128)661–665
   PubMed Web of Science ®Google Scholar
• Weinberg ED. Iron depletion: a defense against intracellular infection and neoplasm. Life Sci 1992; 50(18)1289–1297
   PubMedGoogle Scholar
• Kontoghiorghes GJ, Weinberg ED. Iron: mammalian defence systems, mechanisms of disease and chelation therapy approaches. Blood Rev 1995; 9(1)33–45
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ, Eracleous E, Economides Ch, Kolnagou A. Advances in iron overload therapies. Prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56–252, L1NAll and their combinations. Curr Med Chem 2005; 12(23)2663–2681
   PubMed Web of Science ®Google Scholar
• Fukuda S. Chelating agents used for plutonium and uranium removal in radiation emergency medicine. Curr Med Chem 2005; 12(23)2765–2770
   PubMed Web of Science ®Google Scholar
• Navarro Silvera SA, Rohan TE. Trace elements and cancer risk: a review of the epidemiologic evidence. Cancer Causes Control 2007; 18(1)7–27
   PubMedGoogle Scholar
• Kontoghiorghes GJ, Neocleous K, Kolnagou A. Benefits and risks of deferiprone in iron overload in thalassaemia and other conditions.Comparison of epidemiological and therapeutic aspects with deferoxamine. Drug Saf 2003; 26(8)553–584
   PubMed Web of Science ®Google Scholar
• Ott I, Gust R. Preclinical and clinical studies on the use of platinum complexes for breast cancer treatment. Anticancer Agents Med Chem 2007; 7(1)95–110
   PubMedGoogle Scholar
• Collery P, Keppler B, Madoulet C, Desoize B. Gallium in cancer treatment. Crit Rev Oncol Haematol 2002; 42(3)283–296
   PubMedGoogle Scholar
• Kontoghiorghes GJ, Pattichis K, Neocleous K, Kolnagou A. The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects. Curr Med Chem 2004; 11(16)2161–2183
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ, Kolnagou A. Molecular factors and mechanisms affecting iron and other metal excretion or absorption in health and disease. The role of natural and synthetic chelators. Curr Med Chem 2005; 12(23)2695–2709
   PubMed Web of Science ®Google Scholar
• Richardson DR. Molecular mechanisms of iron uptake by cells and the use of iron chelators for the treatment of cancer. Curr Med Chem 2005; 12(23)2711–2729
   PubMed Web of Science ®Google Scholar
• Forsbeck K, Nillson K, Kontoghiorghes GJ. Variation in iron accumulation, transferrin membrane binding and DNA synthesis in the K562 and U937 cell lines induced by chelators and their iron complexes. Eur J Haematol 1987; 39(4)318–325
   PubMedGoogle Scholar
• Kontoghiorghes GJ. Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions. Hemoglobin 2006; 30(2)183–200
   PubMed Web of Science ®Google Scholar
• Ganeshaguru K, Lally KM, Piga A, Hoffbrand AV, Kontoghiorghes GJ. Cytotoxic mechanisms of iron chelators. Drugs Today 1992; 28(Suppl A)29–34
   Google Scholar
• Cai L, Li X-K, Song Y, Cherian MG. Essentiality, toxicology and chelation therapy of zinc and copper. Curr Med Chem 2005; 12(23)2753–2763
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ, Piga A, Hoffbrand AV. Cytotoxic and DNA inhibitory effects of iron chelators on human leukaemic cell lines. Haematol Oncol 1986; 4(3)195–204
   PubMedGoogle Scholar
• Blatt J, Taylor S, Kontoghiorghes GJ. Comparison of antineuroblastoma activity of desferrioxamine with that of oral iron chelators. Cancer Res 1989; 49(11)2925–2927
   PubMedGoogle Scholar
• Donfrancesco A, Deb G, Domicini C, Angioni A, Caniglia M, De Sio L, Fidani P, Amici A, Helson L. Deferoxamine, cyclophosphamide, etoposide, carboplatin and thotepa (D-CECaT): a new cytoreductive chelation-chemotherapy regimen in patients with advanced neuroblastoma. Am J Clin Oncol 1992; 15(4)319–322
   PubMedGoogle Scholar
• Buss JL, Torti FM, Torti SV. The role of iron chelation in cancer therapy. Curr Med Chem 2003; 10(12)1021–1034
   PubMed Web of Science ®Google Scholar
• Halliwell B. Oxidative stress and cancer: have we moved forward?. Biochem J 2007; 401(1)1–11
   PubMed Web of Science ®Google Scholar
• Afanasiev IB. Superoxide and nitric oxide in pathological conditions associated with iron overload. The effects of antioxidants and chelators. Curr Med Chem 2005; 12(23)2731–2739
   PubMedGoogle Scholar
• Wilson RL. Iron, zinc, free radicals and oxygen in tissue disorders and cancer control. Iron Metabolism, R Porter, DW FitzSimons. Elsevier, Amsterdam 1977; 51: 331–354, Ciba Foundation Symposium, London, UK
   Google Scholar
• Cho KH, Pezzuto JM, Bolton JL, Steele VE, Kelloff GJ, Lee SK, Constantinou A. Selection of cancer chemopreventive agents based on inhibition of topoisomerase II activity. Eur J Cancer 2000; 36(16)2146–2156
   PubMedGoogle Scholar
• Kontoghiorghes GK, Jackson MI, Lunec J. In vitro screening of iron chelators using models of free radical damage. Free Rad Res Commun 1986; 2(2)115–124
   PubMedGoogle Scholar
• Kontoghiorghes G J, Bunce T, Bruckdorfer KR. Differentiation of the therapeutic and toxicological effects of iron and copper chelating drugs in relation to free radical toxicity. Toxicol Lett 1995; 78(Suppl 1)48–49
   Google Scholar
• Eybl V, Caisova D, Koutensky J, Kontoghiorghes GJ. Influence of iron chelators: 1,2-dialkyl-3-hydroxypyridin-4-ones on the lipid peroxidation and glutathione levels in the liver in mice. Arch Toxicol 1991; 14(Suppl)185–187
   Google Scholar
• Kontoghiorghes GJ. Orally active α-ketohydroxypyridine iron chelators. Effects on iron and other metal mobilisations. Acta Haematol 1987; 78(2)212–216
   PubMedGoogle Scholar
• Reeder BJ, Wilson MT. Hemoglobin and myoglobin associated oxidative stress: from molecular mechanisms to disease states. Curr Med Chem 2005; 12(23)2741–2751
   PubMedGoogle Scholar
• Kontoghiorghes GJ. Iron chelation in biochemistry and medicine. Free Radicals, Oxidant Stress and Drug Action, C Rice-Evans. Rechelieu Press, London 1982; 277–303
   Google Scholar
• Swain SM, Vici P. The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review. J Cancer Res Clin Oncol 2004; 130(1)1–7
   PubMed Web of Science ®Google Scholar
• Barnabe N, Zastre JA, Venkataram S, Hassinof BB. Deferiprone protects against doxorubicin–induced myocyte cytotoxicity. Free Rad Biol Med 2002; 33(2)266–275
   PubMed Web of Science ®Google Scholar
• Xu LJ, Jin L, Pan H, Zhang AZ, Wei J, Li PP, Lu WY. Deferiprone protects the isolated atria from cardiotoxicity induced by doxorubicin. Acta Pharmacol Sin 2006; 27(10)1333–1339
   PubMed Web of Science ®Google Scholar
• Hassinof BB, Patel D, Wu X. The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin. Free Radic Biol Med. 2003; 35(11)1469–1479
   PubMed Web of Science ®Google Scholar
• Harrison P, Marwah SS, Hughes RT, Bareford DJ. Non-transferrin bound iron and neutropenia after cytotoxic chemotherapy. J Clin Pathol 1994; 47(4)350–352
   PubMedGoogle Scholar
• Jeremy JY, Kontoghiorghes GJ, Hoffbrand AV, Dandona P. The iron chelators desferrioxamine and 1-alkyl-methyl-3-hydroxypyrid-4-ones inhibit vascular prostacylin synthesis in vitro. Biochem J 1988; 254(1)239–244
   PubMedGoogle Scholar
• Barradas MA, Jeremy J, Kontoghiorghes G.J, Michailidis DP, Hoffbrand AV, Dandona P. Iron chelators inhibit human platelet aggregation, thromboxane A synthesis and lipoxygenase activity. FEBS Lett 1989; 245(1,2)105–109
   PubMedGoogle Scholar
• Kontoghiorghes GJ, Goddard JG, Bartlett AN, Sheppard L. Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Clin Pharm Ther 1990; 48(3)255–261
   PubMed Web of Science ®Google Scholar